BCMA-targeted immunotherapy for multiple myeloma-Reference-Cited by-同舟云学术

BCMA-targeted immunotherapy for multiple myeloma

Published:2020-09-17 Issue:1 Volume:13 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Yu Bo,Jiang Tianbo,Liu Delong^ORCID

Abstract

AbstractB cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

https://link.springer.com/content/pdf/10.1186/s13045-020-00962-7.pdf

Reference185 articles.

1. Raza S, Safyan RA, Lentzsch S. Immunomodulatory drugs (IMiDs) in multiple myeloma. Curr Cancer Drug Targets. 2017;17(9):846–57.

2. Chehab S, Panjic EH, Gleason C, Lonial S, Nooka AK. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Future Oncol. 2018;14(30):3111–21.

3. Le Ray E, Jagannath S, Palumbo A. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma. Expert Rev Hematol. 2016;9(1):91–105.

4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

5. Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J, Wang L. Union for China Lymphoma Investigators of the Chinese Society of Clinical O, Union for China Leukemia Investigators of the Chinese Society of Clinical O: Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):136.

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-11

2. CAR-T: from bench to bedside;Oncohematology;2024-09-03

3. Advancement in “Off-the-Shelf” CAR T-Cell Therapy for Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

4. Expression and Function of FAM72A Gene in Multiple myelomaFAM72A;Current Pharmaceutical Biotechnology;2024-08-08

5. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma;New England Journal of Medicine;2024-08